Related Experiment Videos
Steroid receptors in urological malignancies
Acta Obstetricia Et Gynecologica Scandinavica. Supplement
|January 1, 1981
Summary
Endocrine therapy is crucial for prostate cancer, with androgen receptor levels predicting treatment response. Estrogen therapy acts indirectly, while progestin receptors may indicate sensitivity in prostate cancer cases.
Area of Science:
- Urology
- Endocrinology
- Oncology
Background:
- Three urological cancers—prostate, hypernephroma (renal cell carcinoma), and testicular tumors—are linked to endocrine influence or organs.
- Endocrine therapy is a primary treatment for prostate cancer, has limited use in renal cell carcinoma, and is not employed for testicular cancer.
Purpose of the Study:
- To explore the role of endocrine therapy in urological cancers.
- To investigate the relationship between hormone receptors and treatment outcomes in prostate cancer.
Main Methods:
- Analysis of endocrine therapy's application in prostate, renal cell, and testicular cancers.
- Assessment of androgen, estrogen, and progestin receptor content in prostate cancer tissues.
- Correlation of receptor levels with response to hormonal manipulations.
Main Results:
- Androgen receptor content in primary prostate cancer correlates with response to hormonal therapy.
- Estrogen therapy's effects appear indirect, mediated through the hypothalamo-pituitary axis.
- Progestin receptors are found in both hyperplastic and cancerous prostate tissue, suggesting potential sensitivity to progestin therapy.
Conclusions:
- Endocrine therapy is a dominant treatment for prostate cancer, with androgen receptor assays showing clinical relevance.
- Further refinement of assay methods is needed for widespread clinical application of progestin receptor analysis.